Document Detail


Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2).
MedLine Citation:
PMID:  20548800     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In Part 1 of this review, we discussed how plaque rupture is the most common underlying cause of most cases of unstable angina/non-ST-segment-elevation myocardial infarction (UA/NSTEMI) and how early risk stratification is vital for the timely diagnosis and treatment of acute coronary syndromes (ACS). Now, in Part 2, we focus on the medical therapies and treatment strategies (early conservative vs early invasive) used for UA/NSTEMI. We also discuss results from various large randomized controlled trials that have led to the contemporary standards of practice for, and reduced morbidity and death from, UA/NSTEMI. In summary, ACS involving UA/NSTEMI is associated with high rates of adverse cardiovascular events, despite recent therapeutic advances. Plaque composition and inflammation are more important in the pathogenesis of ACS than is the actual degree of arterial stenosis. As results from new trials challenge our current practices and help us develop the optimal treatment strategy for UA/NSTEMI patients, the cornerstones of contemporary treatment remain early risk stratification and aggressive medical therapy, supplemented by coronary angiography in appropriately selected patients. An early-invasive-treatment strategy is of most benefit to high-risk patients, whereas an early-conservative strategy is recommended for low-risk patients. Adjunctive medical therapy with acetylsalicylic acid, clopidogrel or another adenosine diphosphate antagonist, glycoprotein IIb/IIIa inhibitors, and either low-molecular-weight heparin or unfractionated heparin, in the appropriate setting, further reduces the risk of ischemic events secondary to thrombosis. Short- and long-term inhibition of platelet aggregation should be achieved by appropriately evaluating the risk of bleeding complications in these patients.
Authors:
Shehzad Sami; James T Willerson
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital     Volume:  37     ISSN:  1526-6702     ISO Abbreviation:  Tex Heart Inst J     Publication Date:  2010  
Date Detail:
Created Date:  2010-06-15     Completed Date:  2010-09-27     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8214622     Medline TA:  Tex Heart Inst J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  262-75     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Texas Heart Institute, St. Luke's Episcopal Hospital, The University of Texas Medical School, Houston, Texas 77030, USA. shehzadsami76@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / mortality,  radiography,  surgery,  therapy*
Angina, Unstable / mortality,  radiography,  surgery,  therapy*
Angioplasty, Balloon, Coronary* / adverse effects,  mortality
Anticoagulants / adverse effects
Coronary Angiography
Coronary Artery Bypass* / adverse effects,  mortality
Evidence-Based Medicine
Hemorrhage / chemically induced
Humans
Myocardial Infarction / mortality,  radiography,  surgery,  therapy*
Patient Selection
Platelet Aggregation Inhibitors / adverse effects
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Platelet Aggregation Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A synthesis of the C1-C15 domain of the halichondrins.
Next Document:  Right ventricle-sparing left ventricular resection and replacement with a continuous-flow rotary blo...